Venlo, the Netherlands, June 11, 2024 (GLOBE NEWSWIRE) -- QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the launch of 35 new wet-lab tested digital PCR Microbial DNA Detection Assays for its digital PCR (dPCR) platform QIAcuity, significantly enhancing its offerings in the field of microbial research. The new assays are available on QIAGEN’s comprehensive research platform GeneGlobe and are designed to target a wide range of pathogens responsible for tropical diseases, sexually transmit ...

Ginkgo Bioworks Holdings, Inc. (DNA) has been beaten down lately with too much selling pressure. While the stock has lost 40.2% over the past four weeks, there is light at the end of the tunnel as it is now in oversold territory and Wall Street analysts expect the company to report better earnings than they predicted earlier. Guide to Identifying Oversold Stocks We use Relative Strength Index (RSI), one of the most commonly used technical indicators, for spotting whether a stock is oversold. This is a momen ...

Morgan Stanley recently released its bullish take on the biotech space, driven by anticipated interest rate cuts and a surge in mergers and acquisitions (M&A) activity. The analyst firm states biotech stocks typically outshine the market just before a rate cut. Moreover, increased optimism spurs an uptick in M&A activity, contributing to a more active biotech sector. Hence, discarding underperforming biotech stocks to sell is imperative, as the industry is picking up steam again. This strategic pruning can ...

Venlo, the Netherlands, May 29, 2024 (GLOBE NEWSWIRE) -- QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the launch of its QIAseq Multimodal DNA/RNA Lib Kit. The new kit enables seamless preparation of DNA and RNA libraries for next-generation sequencing (NGS), such as whole genome sequencing (WGS) and whole transcriptome sequencing (WTS), as well as downstream target enrichment based on hybrid-capture from a single sample. The QIAseq Multimodal DNA/RNA Lib Kit facilitates multiomics, the ...

It needs to work within the constraints imposed by these three issues. Thanks to its promises of low-cost bioengineering and biomanufacturing services, Ginkgo Bioworks (DNA 0.70%) could one day be the kind of biotech that everyone else in the biopharma sector wants to work with to advance their own products. Delivering on those plans would make it a smart stock to own as well. But for now, it's still trying to find its footing, and it's a riskier bet than investors may realize. So without further ado, here ...

The number of cell engineering partnerships Ginkgo Bioworks has is way up, but the same can't be said about its stock price. It has been difficult to be a shareholder of Ginkgo Bioworks (DNA 0.70%) over the past year. The stock has collapsed about 72% from its peak last summer. The company's cell engineering foundry is an amazing accomplishment, but sales have stagnated. If this business only needs a little more time for the industries it serves to notice its capabilities, investors who buy now could be gre ...

Ginkgo Bioworks has become a penny stock -- and that's the least of its problems, Ginkgo Bioworks (DNA -3.95%) stock has dropped more than 10% since its latest quarterly report showing a more than 53% decline in Q1 revenue and continued net losses from its business. BTIG analyst Mark Massaro downgraded Ginkgo stock to sell, and lowered his price on this biotech penny stock to just $0.50. It closed Friday at $0.80, so that would be a 37.5% drop. Is Ginkgo stock a sell? Why rate Ginkgo stock a sell? Where sha ...

Can this struggling stock turn things around? Ginkgo Bioworks (DNA -3.98%) is a cell programming company that claims to have large addressable markets (for bioengineered products) in multiple industries in which it can play a key role, and that those are worth trillions of dollars in total. But the problem is it may take more than a decade for those markets to reach that kind of size. Investors could require a lot of patience. While there may be a lot of potential for the business in the long run, investors ...

A few enterprising businesses are marketing themselves differently. As you may have heard, there's a new trend in biotech lingo wherein companies call themselves "TechBio" rather than "biotech" to emphasize their forward-thinking about the role of information technology. Biotechs like Ginkgo Bioworks (DNA 2.63%), Recursion Pharmaceuticals (RXRX 6.01%), and Schrödinger (SDGR 0.30%) could easily be described by the term, and some, like Recursion, even describe themselves that way. But what does this new term ...

BOSTON, May 15, 2024 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced that management will be participating in two investor conferences in May. TD Cowen's 2nd Annual Sustainability Week: Ginkgo's Senior Director of Policy and Partnerships, Ryan Morhard, will participate in the virtual Sustainable API Manufacturing panel at 4:25 pm ET on May 22, 2024. Leerink Partners Healthcare Crossroads Conference: Ginkgo's Chief Busi ...